開放隅角緑内障（OAG）の世界市場レポート 2025年

開放隅角緑内障（OAG）市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.5％で84億2,000万米ドルに成長します。予測期間中の成長は、併用療法に対する需要の増加、個別化医療の重視の高まり、緑内障治療に対する償還政策の改善、生活習慣に起因する眼疾患の増加、非侵襲的診断法に対する嗜好の高まりなどの要因によるものと考えられます。予測期間を形成すると予想される主な動向には、緑内障診断におけるAIの採用の拡大、緑内障の外来手術へのシフト、徐放性緑内障インプラントの使用の増加、眼圧モニタリングのためのウェアラブル技術の統合の拡大、医療機器の製造における持続可能性への注目の高まりなどがあります。

眼疾患に対する意識の高まりが、今後の開放隅角緑内障（OAG）市場の成長を牽引すると予想されます。目の病気とは、目の構造、機能、視力に影響を及ぼす状態を指し、ドライアイなどの軽微な問題から緑内障や黄斑変性症などの重篤な状態にまで及ぶ。これらの疾患の有病率の上昇は、人口の高齢化、スクリーン使用時間の増加、糖尿病罹患率の上昇、環境汚染、目の健康に悪影響を及ぼすライフスタイルの選択などの要因に影響されています。開放隅角緑内障（OAG）は、特に高齢者の失明の主な原因であり、取り返しのつかない視力低下を防ぐために、定期的な眼科検診、早期発見、適時治療の重要性を強調しています。例えば、2023年10月、英国を拠点とする視力喪失の慈善団体である英国王立盲人協会（RNIB）は、英国における眼科外来予約が2021/22年に800万人を突破し、最も要請の多い診療科になったと報告しました。さらに、現在200万人を超える視力喪失者は、2050年までに倍増して400万人を超えると予想されています。その結果、目の病気に対する意識の高まりが開放隅角緑内障（OAG）市場の成長を後押ししています。

開放隅角緑内障（OAG）市場の主要企業は、低侵襲緑内障装置（MIGD）などの革新的ソリューションの開発に注力しており、従来の治療への依存を減らしつつ、原発開放隅角緑内障を管理するための高度で侵襲性の低い選択肢を提供しています。低侵襲緑内障装置（MIGD）には、小さな切開と眼組織への最小限の障害によって緑内障患者の眼圧を下げることを目的とした様々な手術用インプラントや技術が含まれます。例えば、2023年12月、ベルギーに本社を置く医療技術企業iSTAR Medical社は、オランダでMINIjectを発表しました。この原発性開放隅角緑内障の生物学的統合治療は、独自の多孔性STAR素材を用いて体液の流出を改善し、眼圧を低下させる。MINIjectは、従来の治療法の必要性を減らすことにより、緑内障治療に大きな進歩をもたらし、不可逆的失明の主な原因である緑内障に、より安全で効果的な治療法を提供します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界開放隅角緑内障（OAG） PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の開放隅角緑内障（OAG）市場：成長率分析
• 世界の開放隅角緑内障（OAG）市場の実績：規模と成長, 2019-2024
• 世界の開放隅角緑内障（OAG）市場の予測：規模と成長, 2024-2029, 2034F
• 世界開放隅角緑内障（OAG）総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の開放隅角緑内障（OAG）市場：疾患タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 開放隅角緑内障
• 閉塞隅角緑内障
• その他の病気の種類
• 世界の開放隅角緑内障（OAG）市場薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• プロスタグランジン類似体
• ベータ遮断薬
• アドレナリン作動薬
• 炭酸脱水酵素阻害剤
• その他の薬物クラス
• 世界の開放隅角緑内障（OAG）市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• ホームケア
• 専門クリニック
• その他のエンドユーザー
• 世界の開放隅角緑内障（OAG）市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• オンライン薬局
• 小売薬局
• 世界の開放隅角緑内障（OAG）市場開放隅角緑内障の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 原発開放隅角緑内障（POAG）
• 続発開放隅角緑内障
• 世界の開放隅角緑内障（OAG）市場閉塞隅角緑内障の分類（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 急性閉塞隅角緑内障
• 慢性閉塞隅角緑内障
• 世界の開放隅角緑内障（OAG）市場、その他の疾患タイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 正常眼圧緑内障
• 先天性緑内障
• 続発性緑内障

第7章 地域別・国別分析

• 世界の開放隅角緑内障（OAG）市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の開放隅角緑内障（OAG）市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 開放隅角緑内障（OAG）市場：競合情勢
• 開放隅角緑内障（OAG）市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Teva Pharmaceutical Industries Ltd.
• Boston Scientific
• Alcon Inc.
• Bausch Health Companies Inc.
• Hoya Corporation
• Sun Pharmaceutical Industries Ltd.
• Santen Pharmaceuticals
• Mallinckrodt Pharmaceuticals
• Thea Pharma
• Glaukos Corporation
• Quantel Medical
• EyePoint Pharmaceuticals Inc.
• iSTAR Medical
• Nicox Ophthalmics
• Visus Therapeutics

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 開放隅角緑内障（OAG）市場2029：新たな機会を提供する国
• 開放隅角緑内障（OAG）市場2029：新たな機会を提供するセグメント
• 開放隅角緑内障（OAG）市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Open-angle glaucoma (OAG) is a chronic and progressive eye condition in which the drainage canals in the eye gradually become blocked, causing an increase in intraocular pressure that damages the optic nerve. This damage typically occurs without noticeable symptoms until significant vision loss has occurred. Treatment focuses on lowering intraocular pressure to prevent further optic nerve damage and preserve vision through medications, laser therapies, or surgical procedures.

The main types of open-angle glaucoma (OAG) include open-angle glaucoma, angle-closure glaucoma, and other variants. Open-angle glaucoma is characterized by increased intraocular pressure, which leads to slow optic nerve damage and potential vision loss, often without early warning signs. The medications used to treat this condition include prostaglandin analogs, beta blockers, adrenergic agonists, carbonic anhydrase inhibitors, and others. The primary end users of these treatments include hospitals, homecare settings, specialty clinics, and more. These treatments are distributed through various channels such as hospital pharmacies, online pharmacies, and retail pharmacies.

The open-angle glaucoma (OAG) market research report is one of a series of new reports from The Business Research Company that provides open-angle glaucoma (OAG) market statistics, including open-angle glaucoma (OAG) industry global market size, regional shares, competitors with open-angle glaucoma (OAG) market share, detailed open-angle glaucoma (OAG) market segments, market trends and opportunities, and any further data you may need to thrive in the open-angle glaucoma (OAG) industry. This open-angle glaucoma (OAG) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The open-angle glaucoma (OAG) market size has grown strongly in recent years. It will grow from $6.13 billion in 2024 to $6.55 billion in 2025 at a compound annual growth rate (CAGR) of 6.8%. The growth during the historic period can be attributed to factors such as the rising prevalence of glaucoma in aging populations, increasing awareness about the early detection of eye diseases, higher healthcare expenditure, government initiatives supporting vision care programs, and the global expansion of ophthalmology practices.

The open-angle glaucoma (OAG) market size is expected to see strong growth in the next few years. It will grow to $8.42 billion in 2029 at a compound annual growth rate (CAGR) of 6.5%. The growth during the forecast period can be attributed to factors such as the increasing demand for combination therapies, a growing emphasis on personalized medicine, improved reimbursement policies for glaucoma treatments, a rise in lifestyle-induced ocular conditions, and a growing preference for non-invasive diagnostic methods. Key trends expected to shape the forecast period include the growing adoption of AI in glaucoma diagnostics, a shift toward outpatient surgical procedures for glaucoma, an increased use of sustained-release glaucoma implants, greater integration of wearable technology for monitoring intraocular pressure, and a heightened focus on sustainability in the manufacturing of medical devices.

The increasing awareness of eye diseases is expected to drive the growth of the open-angle glaucoma (OAG) market in the future. Eye illnesses refer to conditions that affect the eyes' structure, function, or vision, ranging from minor issues such as dry eye to more severe conditions such as glaucoma and macular degeneration. The rising prevalence of these conditions is influenced by factors such as aging populations, extended screen time, higher rates of diabetes, environmental pollution, and lifestyle choices that negatively affect eye health. Open-angle glaucoma (OAG), which is a leading cause of blindness, particularly in older adults, highlights the importance of regular eye exams, early detection, and timely treatment to prevent irreversible vision loss. For example, in October 2023, the Royal National Institute of Blind People (RNIB), a UK-based charity for sight loss, reported that eye care outpatient appointments in the UK surpassed eight million in 2021/22, making it the most requested medical specialty. Furthermore, the number of people experiencing sight loss, which currently exceeds two million, is expected to double to over four million by 2050. As a result, the rising awareness of eye illnesses is fueling the growth of the open-angle glaucoma (OAG) market.

Leading companies in the open-angle glaucoma (OAG) market are focusing on the development of innovative solutions, such as minimally invasive glaucoma devices (MIGDs), to offer advanced, less invasive options for managing primary open-angle glaucoma while reducing dependence on traditional treatments. A minimally invasive glaucoma device (MIGD) includes various surgical implants and techniques aimed at lowering intraocular pressure in glaucoma patients through small incisions and minimal disturbance to ocular tissues. For example, in December 2023, iSTAR Medical, a medtech company based in Belgium, introduced MINIject in the Netherlands. This bio-integrating treatment for primary open-angle glaucoma uses a unique porous STAR material to improve fluid outflow and lower intraocular pressure. By reducing the need for traditional therapies, MINIject marks a significant advancement in glaucoma treatment, providing a safer and more effective management option for this major cause of irreversible blindness.

In July 2024, Alcon Inc., an ophthalmology company based in Switzerland, acquired BELKIN Vision Ltd. for $81 million. This acquisition is intended to strengthen Alcon's glaucoma portfolio by incorporating the direct selective laser trabeculoplasty (DSLT) device, an advanced first-line laser treatment for managing open-angle glaucoma. The acquisition supports Alcon's strategy to expand global access to innovative and minimally invasive glaucoma treatments. BELKIN Vision Ltd., based in Israel, is a medical device company that specializes in providing devices for the treatment of open-angle glaucoma.

Major players in the open-angle glaucoma (OAG) market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc, Novartis AG, Amgen Inc., Teva Pharmaceutical Industries Ltd., Boston Scientific, Alcon Inc., Bausch Health Companies Inc., Hoya Corporation, Sun Pharmaceutical Industries Ltd., Santen Pharmaceuticals, Mallinckrodt Pharmaceuticals, Thea Pharma, Glaukos Corporation, Quantel Medical, EyePoint Pharmaceuticals Inc., iSTAR Medical, Nicox Ophthalmics, Visus Therapeutics, Peregrine Eye Laser and Institute, and Inotek Pharmaceuticals.

North America was the largest region in the open-angle glaucoma (OAG) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in open-angle glaucoma (OAG) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the open-angle glaucoma (OAG) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The open-angle glaucoma (OAG) market consists of revenues earned by entities by providing services such as optometric services, surgical interventions, medication management, and patient education and support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The open-angle glaucoma (OAG) market also includes sales of tonometers, visual field analyzers, and lubricating eye drops. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Open-Angle Glaucoma (OAG) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on open-angle glaucoma (oag) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for open-angle glaucoma (oag) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The open-angle glaucoma (oag) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Disease Type: Open Angle Glaucoma; Angle Closure Glaucoma; Other Disease Type
• 2) By Drug Class: Prostaglandin Analog; Beta Blockers; Adrenergic Agonist; Carbonic Anhydrase Inhibitors; Others Drug Class
• 3) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
• 4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
• Subsegments:
• 1) By Open Angle Glaucoma (OAG): Primary Open-Angle Glaucoma (POAG); Secondary Open-Angle Glaucoma
• 2) By Angle Closure Glaucoma: Acute Angle-Closure Glaucoma; Chronic Angle-Closure Glaucoma
• 3) By Other Disease Type: Normal-Tension Glaucoma; Congenital Glaucoma; Secondary Glaucoma
• Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; AbbVie Inc; Novartis AG; Amgen Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Open-Angle Glaucoma (OAG) Market Characteristics

3. Open-Angle Glaucoma (OAG) Market Trends And Strategies

4. Open-Angle Glaucoma (OAG) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Open-Angle Glaucoma (OAG) Growth Analysis And Strategic Analysis Framework

• 5.1. Global Open-Angle Glaucoma (OAG) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Open-Angle Glaucoma (OAG) Market Growth Rate Analysis
• 5.4. Global Open-Angle Glaucoma (OAG) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Open-Angle Glaucoma (OAG) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Open-Angle Glaucoma (OAG) Total Addressable Market (TAM)

6. Open-Angle Glaucoma (OAG) Market Segmentation

• 6.1. Global Open-Angle Glaucoma (OAG) Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Open Angle Glaucoma
• Angle Closure Glaucoma
• Other Disease Type
• 6.2. Global Open-Angle Glaucoma (OAG) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prostaglandin Analog
• Beta Blockers
• Adrenergic Agonist
• Carbonic Anhydrase Inhibitors
• Others Drug Class
• 6.3. Global Open-Angle Glaucoma (OAG) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Other End Users
• 6.4. Global Open-Angle Glaucoma (OAG) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• 6.5. Global Open-Angle Glaucoma (OAG) Market, Sub-Segmentation Of Open Angle Glaucoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Primary Open-Angle Glaucoma (POAG)
• Secondary Open-Angle Glaucoma
• 6.6. Global Open-Angle Glaucoma (OAG) Market, Sub-Segmentation Of Angle Closure Glaucoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acute Angle-Closure Glaucoma
• Chronic Angle-Closure Glaucoma
• 6.7. Global Open-Angle Glaucoma (OAG) Market, Sub-Segmentation Of Other Disease Type, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Normal-Tension Glaucoma
• Congenital Glaucoma
• Secondary Glaucoma

7. Open-Angle Glaucoma (OAG) Market Regional And Country Analysis

• 7.1. Global Open-Angle Glaucoma (OAG) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Open-Angle Glaucoma (OAG) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Open-Angle Glaucoma (OAG) Market

• 8.1. Asia-Pacific Open-Angle Glaucoma (OAG) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Open-Angle Glaucoma (OAG) Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Open-Angle Glaucoma (OAG) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Open-Angle Glaucoma (OAG) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Open-Angle Glaucoma (OAG) Market

• 9.1. China Open-Angle Glaucoma (OAG) Market Overview
• 9.2. China Open-Angle Glaucoma (OAG) Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Open-Angle Glaucoma (OAG) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Open-Angle Glaucoma (OAG) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Open-Angle Glaucoma (OAG) Market

• 10.1. India Open-Angle Glaucoma (OAG) Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Open-Angle Glaucoma (OAG) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Open-Angle Glaucoma (OAG) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Open-Angle Glaucoma (OAG) Market

• 11.1. Japan Open-Angle Glaucoma (OAG) Market Overview
• 11.2. Japan Open-Angle Glaucoma (OAG) Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Open-Angle Glaucoma (OAG) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Open-Angle Glaucoma (OAG) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Open-Angle Glaucoma (OAG) Market

• 12.1. Australia Open-Angle Glaucoma (OAG) Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Open-Angle Glaucoma (OAG) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Open-Angle Glaucoma (OAG) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Open-Angle Glaucoma (OAG) Market

• 13.1. Indonesia Open-Angle Glaucoma (OAG) Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Open-Angle Glaucoma (OAG) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Open-Angle Glaucoma (OAG) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Open-Angle Glaucoma (OAG) Market

• 14.1. South Korea Open-Angle Glaucoma (OAG) Market Overview
• 14.2. South Korea Open-Angle Glaucoma (OAG) Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Open-Angle Glaucoma (OAG) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Open-Angle Glaucoma (OAG) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Open-Angle Glaucoma (OAG) Market

• 15.1. Western Europe Open-Angle Glaucoma (OAG) Market Overview
• 15.2. Western Europe Open-Angle Glaucoma (OAG) Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Open-Angle Glaucoma (OAG) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Open-Angle Glaucoma (OAG) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Open-Angle Glaucoma (OAG) Market

• 16.1. UK Open-Angle Glaucoma (OAG) Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Open-Angle Glaucoma (OAG) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Open-Angle Glaucoma (OAG) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Open-Angle Glaucoma (OAG) Market

• 17.1. Germany Open-Angle Glaucoma (OAG) Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Open-Angle Glaucoma (OAG) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Open-Angle Glaucoma (OAG) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Open-Angle Glaucoma (OAG) Market

• 18.1. France Open-Angle Glaucoma (OAG) Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Open-Angle Glaucoma (OAG) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Open-Angle Glaucoma (OAG) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Open-Angle Glaucoma (OAG) Market

• 19.1. Italy Open-Angle Glaucoma (OAG) Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Open-Angle Glaucoma (OAG) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Open-Angle Glaucoma (OAG) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Open-Angle Glaucoma (OAG) Market

• 20.1. Spain Open-Angle Glaucoma (OAG) Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Open-Angle Glaucoma (OAG) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Open-Angle Glaucoma (OAG) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Open-Angle Glaucoma (OAG) Market

• 21.1. Eastern Europe Open-Angle Glaucoma (OAG) Market Overview
• 21.2. Eastern Europe Open-Angle Glaucoma (OAG) Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Open-Angle Glaucoma (OAG) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Open-Angle Glaucoma (OAG) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Open-Angle Glaucoma (OAG) Market

• 22.1. Russia Open-Angle Glaucoma (OAG) Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Open-Angle Glaucoma (OAG) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Open-Angle Glaucoma (OAG) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Open-Angle Glaucoma (OAG) Market

• 23.1. North America Open-Angle Glaucoma (OAG) Market Overview
• 23.2. North America Open-Angle Glaucoma (OAG) Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Open-Angle Glaucoma (OAG) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Open-Angle Glaucoma (OAG) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Open-Angle Glaucoma (OAG) Market

• 24.1. USA Open-Angle Glaucoma (OAG) Market Overview
• 24.2. USA Open-Angle Glaucoma (OAG) Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Open-Angle Glaucoma (OAG) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Open-Angle Glaucoma (OAG) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Open-Angle Glaucoma (OAG) Market

• 25.1. Canada Open-Angle Glaucoma (OAG) Market Overview
• 25.2. Canada Open-Angle Glaucoma (OAG) Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Open-Angle Glaucoma (OAG) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Open-Angle Glaucoma (OAG) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Open-Angle Glaucoma (OAG) Market

• 26.1. South America Open-Angle Glaucoma (OAG) Market Overview
• 26.2. South America Open-Angle Glaucoma (OAG) Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Open-Angle Glaucoma (OAG) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Open-Angle Glaucoma (OAG) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Open-Angle Glaucoma (OAG) Market

• 27.1. Brazil Open-Angle Glaucoma (OAG) Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Open-Angle Glaucoma (OAG) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Open-Angle Glaucoma (OAG) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Open-Angle Glaucoma (OAG) Market

• 28.1. Middle East Open-Angle Glaucoma (OAG) Market Overview
• 28.2. Middle East Open-Angle Glaucoma (OAG) Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Open-Angle Glaucoma (OAG) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Open-Angle Glaucoma (OAG) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Open-Angle Glaucoma (OAG) Market

• 29.1. Africa Open-Angle Glaucoma (OAG) Market Overview
• 29.2. Africa Open-Angle Glaucoma (OAG) Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Open-Angle Glaucoma (OAG) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Open-Angle Glaucoma (OAG) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Open-Angle Glaucoma (OAG) Market Competitive Landscape And Company Profiles

• 30.1. Open-Angle Glaucoma (OAG) Market Competitive Landscape
• 30.2. Open-Angle Glaucoma (OAG) Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Open-Angle Glaucoma (OAG) Market Other Major And Innovative Companies

• 31.1. Teva Pharmaceutical Industries Ltd.
• 31.2. Boston Scientific
• 31.3. Alcon Inc.
• 31.4. Bausch Health Companies Inc.
• 31.5. Hoya Corporation
• 31.6. Sun Pharmaceutical Industries Ltd.
• 31.7. Santen Pharmaceuticals
• 31.8. Mallinckrodt Pharmaceuticals
• 31.9. Thea Pharma
• 31.10. Glaukos Corporation
• 31.11. Quantel Medical
• 31.12. EyePoint Pharmaceuticals Inc.
• 31.13. iSTAR Medical
• 31.14. Nicox Ophthalmics
• 31.15. Visus Therapeutics

32. Global Open-Angle Glaucoma (OAG) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Open-Angle Glaucoma (OAG) Market

34. Recent Developments In The Open-Angle Glaucoma (OAG) Market

35. Open-Angle Glaucoma (OAG) Market High Potential Countries, Segments and Strategies

• 35.1 Open-Angle Glaucoma (OAG) Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Open-Angle Glaucoma (OAG) Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Open-Angle Glaucoma (OAG) Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer